89bio initiates phase 3 enlighten-fibrosis trial of pegozafermin in non-cirrhotic metabolic dysfunction-associated steatohepatitis (mash) patients with fibrosis

—co-primary endpoints in enlighten-fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic mash (fibrosis stage f2-f3) patients—

ETNB Ratings Summary

ETNB Quant Ranking